Although FASN inhibitors, including C75, C93, GSK837149A, Orlistat and TVB-3166, have demonstrated preclinical antitumor activity in cancer cell lines and xenograft models (45, 48), none of these compounds have been tested in cancer patients due to side effects. The gene discussed is FASN; the disease is cancer.